OncoMatch/Clinical Trials/NCT06839066
A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
Is NCT06839066 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including HLX43 DOSE 1 and HLX43 DOSE 2 for nasopharyngeal carcinoma (npc).
Treatment: HLX43 DOSE 1 · HLX43 DOSE 2 · HLX43 DOSE 3 — The study is to explore the reasonable dosage and to evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in patients with recurrent/metastatic Nasopharyngeal Carcinoma (NPC) who failed or are intolerant to second-line herapy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) any tested (testing required; no eligibility threshold specified)
Disease stage
Metastatic disease required
recurrent/metastatic nasopharyngeal carcinoma; at least one measurable lesion per RECIST v1.1
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: chemotherapy
failed or are intolerant to at least two prior lines of chemotherapy (including at least one platinum-based regimen)
Must have received: platinum-based chemotherapy
including at least one platinum-based regimen
Must have received: anti-PD-1 therapy
failed or are intolerant to...PD-1/PD-L1 inhibitor therapy
Must have received: anti-PD-L1 therapy
failed or are intolerant to...PD-1/PD-L1 inhibitor therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06839066 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received chemotherapy and platinum-based chemotherapy.
Does this trial require CD274?
Yes, CD274 any tested is a required biomarker for enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify